137 related articles for article (PubMed ID: 23179402)
1. CYP3A4*1B polymorphism and cancer risk: a HuGE review and meta-analysis.
Zhou LP; Yao F; Luan H; Wang YL; Dong XH; Zhou WW; Wang QH
Tumour Biol; 2013 Apr; 34(2):649-60. PubMed ID: 23179402
[TBL] [Abstract][Full Text] [Related]
2. CYP3A4*1B Polymorphism and Cancer Risk: A Meta-Analysis Based on 55 Case-control Studies.
Zheng Y; Xu Y; Zhou BY; Sun L; Yu PB; Zhang L; Xu J; Wang JJ
Ann Clin Lab Sci; 2018 Jul; 48(4):538-545. PubMed ID: 30143500
[TBL] [Abstract][Full Text] [Related]
3. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer.
Spurdle AB; Goodwin B; Hodgson E; Hopper JL; Chen X; Purdie DM; McCredie MR; Giles GG; Chenevix-Trench G; Liddle C
Pharmacogenetics; 2002 Jul; 12(5):355-66. PubMed ID: 12142725
[TBL] [Abstract][Full Text] [Related]
4. CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review.
Keshava C; McCanlies EC; Weston A
Am J Epidemiol; 2004 Nov; 160(9):825-41. PubMed ID: 15496535
[TBL] [Abstract][Full Text] [Related]
5. Genetic association in
Bellah SF; Salam MA; Billah SMS; Karim MR
Ann Hum Biol; 2023 Feb; 50(1):63-74. PubMed ID: 36688864
[TBL] [Abstract][Full Text] [Related]
6. Correlations between CYP3A4 polymorphism and susceptibility to breast cancer in Chinese Han population.
Liu X; Huang X; Zhang S; Niu F; Ouyang Y; Shou Z; Liu J
Int J Clin Oncol; 2019 Feb; 24(2):179-188. PubMed ID: 30218411
[TBL] [Abstract][Full Text] [Related]
7. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose.
Dally H; Edler L; Jäger B; Schmezer P; Spiegelhalder B; Dienemann H; Drings P; Schulz V; Kayser K; Bartsch H; Risch A
Pharmacogenetics; 2003 Oct; 13(10):607-18. PubMed ID: 14515059
[TBL] [Abstract][Full Text] [Related]
8. Association between the CYP3A4 and CYP3A5 polymorphisms and cancer risk: a meta-analysis and meta-regression.
He XF; Liu ZZ; Xie JJ; Wang W; Du YP; Chen Y; Wei W
Tumour Biol; 2014 Oct; 35(10):9859-77. PubMed ID: 24989928
[TBL] [Abstract][Full Text] [Related]
9. Association of CYP3A4, CYP3A5 polymorphisms with lung cancer risk in Bangladeshi population.
Islam MS; Mostofa AG; Ahmed MU; Bin Sayeed MS; Hassan MR; Hasnat A
Tumour Biol; 2014 Feb; 35(2):1671-8. PubMed ID: 24085358
[TBL] [Abstract][Full Text] [Related]
10. Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men.
Bangsi D; Zhou J; Sun Y; Patel NP; Darga LL; Heilbrun LK; Powell IJ; Severson RK; Everson RB
Urol Oncol; 2006; 24(1):21-7. PubMed ID: 16414488
[TBL] [Abstract][Full Text] [Related]
11. The PXR rs7643645 polymorphism is associated with the risk of higher prostate-specific antigen levels in prostate cancer patients.
Reyes-Hernández OD; Vega L; Jiménez-Ríos MA; Martínez-Cervera PF; Lugo-García JA; Hernández-Cadena L; Ostrosky-Wegman P; Orozco L; Elizondo G
PLoS One; 2014; 9(6):e99974. PubMed ID: 24924803
[TBL] [Abstract][Full Text] [Related]
12. Murine Double Minute 2 SNP T309G Polymorphism and Urinary Tract Cancer Risk: A Meta-Analysis.
Ding H; Dai Y; Ning Z; Fan N; Wang Z; Li P; Zhang L; Tao Y; Wang H
Medicine (Baltimore); 2016 Mar; 95(12):e2941. PubMed ID: 27015167
[TBL] [Abstract][Full Text] [Related]
13. The CYP3A4 *1B polymorphism and prostate cancer susceptibility in a Portuguese population.
Nogal A; Coelho A; Catarino R; Morais A; Lobo F; Medeiros R
Cancer Genet Cytogenet; 2007 Sep; 177(2):149-52. PubMed ID: 17854673
[TBL] [Abstract][Full Text] [Related]
14. The Influence of CYP3A4 Polymorphism in Sex Steroids as a Risk Factor for Breast Cancer.
Veiga MG; Felizi RT; Reis DG; Carelli Filho I; Fernandes CE; Souto RPD; Oliveira E
Rev Bras Ginecol Obstet; 2018 Nov; 40(11):699-704. PubMed ID: 30336495
[TBL] [Abstract][Full Text] [Related]
15. Estimation of CYP3A4*1B single nucleotide polymorphism in patients with recurrent Major Depressive Disorder.
Świechowski R; Jeleń A; Mirowski M; Talarowska M; Gałecki P; Pietrzak J; Wodziński D; Balcerczak E
Mol Genet Genomic Med; 2019 Jun; 7(6):e669. PubMed ID: 31025537
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent.
Taioli E; Sears V; Watson A; Flores-Obando RE; Jackson MD; Ukoli FA; de Syllos Cólus IM; Fernandez P; McFarlane-Anderson N; Ostrander EA; Rodrigues IS; Stanford JL; Taylor JA; Tulloch-Reid M; Ragin CC
Prostate; 2013 May; 73(6):668-76. PubMed ID: 23129512
[TBL] [Abstract][Full Text] [Related]
17. CYP3A5*3 polymorphism and cancer risk: a meta-analysis and meta-regression.
Wang BS; Liu Z; Xu WX; Sun SL
Tumour Biol; 2013 Aug; 34(4):2357-66. PubMed ID: 23584898
[TBL] [Abstract][Full Text] [Related]
18. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):75-81. PubMed ID: 19802823
[TBL] [Abstract][Full Text] [Related]
19. Associations of ERCC4 rs1800067 polymorphism with cancer risk: an updated meta-analysis.
Yuan Q; Liu JW; Xing CZ; Yuan Y
Asian Pac J Cancer Prev; 2014; 15(18):7639-44. PubMed ID: 25292041
[TBL] [Abstract][Full Text] [Related]
20. EGF +61A>G polymorphism and gastrointestinal cancer risk: a HuGE review and meta-analysis.
Piao Y; Liu Z; Ding Z; Xu L; Guo F; Sun Q; Xie X
Gene; 2013 Apr; 519(1):26-33. PubMed ID: 23403233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
